Navidea Biopharmaceuticals (NAVB) Misses Q4 EPS by 2c

March 6, 2014 7:48 AM

Navidea Biopharmaceuticals (NYSE: NAVB) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found